Document is current
Any future updates will be listed below
-
Authors
Goldberg, Gregory W. https://orcid.org/0000-0002-5022-9976
Kogenaru, Manjunatha https://orcid.org/0000-0001-6570-7857
Keegan, Sarah
Haase, Max A. B.
Kagermazova, Larisa https://orcid.org/0009-0004-7494-284X
Arias, Mauricio A.
Onyebeke, Kenenna
Adams, Samantha
Beyer, Daniel K.
Fenyö, David
Noyes, Marcus B. https://orcid.org/0000-0002-3065-1096
Boeke, Jef D. https://orcid.org/0000-0001-5322-4946
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (F32GM137482, K99GM147604, R01GM118851)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1HG009491)
- License Information
-
More Information
Article History
Received: 9 August 2024
Accepted: 18 November 2024
First Online: 27 November 2024
Competing interests
: Jef Boeke is a Founder and Director of CDI Labs, Inc., a Founder of and consultant to Opentrons LabWorks/Neochromosome, Inc, and serves or served on the Scientific Advisory Board of the following: CZ Biohub New York, LLC, Logomix, Inc., Modern Meadow, Inc., Rome Therapeutics, Inc., SeaHub, Seattle, WA, Tessera Therapeutics, Inc. and the Wyss Institute. Marcus Noyes is a founder of TBG Therapeutics, Inc. New York University filed a provisional patent application (No. 63/582,731) for findings described in this work, with Gregory Goldberg, Marcus Noyes, and Jef Boeke listed as inventors. The other authors declare no competing interests.
